We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

The National Center for Genome Resources Studies Childhood Diseases Using febit’s DNA Capture Method

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
febit’s HybSelect™ technology for sequence capture enables targeted Next-Generation Sequencing, furthers development of genetic tests for childhood diseases.

The National Center for Genome Resources (NCGR) has selected febit’s DNA-capture method, HybSelect™, to re-sequence the exons of genes involved in over 400 of the most devastating childhood diseases with the ultimate goal of developing genetic tests to detect carrier status for recessive genetic diseases in prospective parents.

In this collaboration the NCGR will bring its experience in comprehensive Illumina sequencing studies to febit’s automated HybSelect technology for targeted re-sequencing to develop and test highly parallel analysis. This will enhance the multiplexing capability of HybSelect to perform surveys in large-cohort studies.

NCGR scientists searched for a technology that would allow them to capture the exons of interest for re-sequencing. febit’s automated HybSelect technology for targeted, hybridization-based DNA enrichment supports deep sequencing studies resulting in high coverage results. The Geniom RT Analyzerâ provides the easy-to-use and highly automated capturing of the desired DNA fragments for further Next-Generation Sequencing (NGS).

Stephen Kingsmore, CEO of NCGR, stated: “We are impressed by the unique flexibility and scalability of febit’s HybSelect technology and with the ease of integration in production sequencing with Illumina Genome Analyzers. In partnership with the Beyond Batten Disease Foundation, we aim to combine these technologies to offer highly cost effective screening for rare childhood diseases.”